NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 82 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 1.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $55,770 | -18.7% | 13,669 | 0.0% | 0.01% | -20.0% |
| Q4 2022 | $68,618 | -61.7% | 13,669 | 0.0% | 0.02% | -64.3% |
| Q3 2022 | $179,000 | +2.3% | 13,669 | 0.0% | 0.04% | -10.6% |
| Q2 2022 | $175,000 | -15.9% | 13,669 | 0.0% | 0.05% | -9.6% |
| Q1 2022 | $208,000 | -14.0% | 13,669 | 0.0% | 0.05% | +10.6% |
| Q4 2021 | $242,000 | -15.7% | 13,669 | 0.0% | 0.05% | +4.4% |
| Q3 2021 | $287,000 | -20.1% | 13,669 | -25.0% | 0.04% | +2.3% |
| Q2 2021 | $359,000 | -32.3% | 18,225 | 0.0% | 0.04% | -55.1% |
| Q1 2021 | $530,000 | -4.0% | 18,225 | 0.0% | 0.10% | +75.0% |
| Q4 2020 | $552,000 | -4.8% | 18,225 | -50.0% | 0.06% | -65.4% |
| Q3 2020 | $580,000 | -39.5% | 36,451 | -25.0% | 0.16% | -47.6% |
| Q2 2020 | $959,000 | – | 48,602 | – | 0.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |